

Tentative Agenda & Scientific Program

Day 1 - WORKSHOPS: Wednesday June 3rd

George D. Behrakis Grand Hall/Creese Student Center, Drexel University, 3210 Chestnut St, Philadelphia, PA 19104. Street View: <https://maps.app.goo.gl/4UbTEi1KLqfVuRd8A>

10:30AM	Registration <i>(Continued all day)</i>	
12:00 – 13:00	Grant writing session/NIH/RFAs Moderator: Fatah Kashanchi	
13:00 – 15:00	Workshop 1 Public Health, Transmission & Community Engagement <i>(Leandro Sereno & Damian Purcell)</i>	Workshop 2 Molecular Virology and Immunopathogenesis <i>(Chairs: Edward Harhaj & B. Hilda Ye)</i>
	<p style="text-align: center;">HTLV-1 Pre-Exposure Prophylaxis Working Group PRERECORD - Fabiola Martin, Australia</p> <p style="text-align: center;">Brasil Saudável”, A bold agenda to eliminate HTLV - a Public Health Problem Pamela Gaspar, Brazil</p> <p style="text-align: center;">Ensuring blood safety, and interrupting HTLV transmission Sheila O’Brien, Univ Ottawa</p> <p style="text-align: center;">Public health impact of HTLV in vulnerable populations and geographic areas in Peru Eduardo Gotuzzo, Peru</p> <p style="text-align: center;">HTLV-1 mother-to-child transmission Andrea Thoma-Kress, Germany</p> <p style="text-align: center;">Status of HTLV-1 in Aboriginals communities Lloyd Einsiedel, Australia</p> <p style="text-align: center;">HTLV challenges and opportunities in the international public health agenda Josh Anzinger</p>	<p style="text-align: center;">Genetic landscape and clonal evolution of ATLL Aileen Rowan, UK</p> <p style="text-align: center;">HTLV-1 particle assembly and transmission Louis Mansky, USA</p> <p style="text-align: center;">Mechanisms of latent HTLV-1 infection, clonal evolution and genetic landscape of ATLL Yorifumi Satou, Japan</p> <p style="text-align: center;">The role of transcription regulation in the life cycle of HTLV-1 and BLV Luc Willems, Belgium</p> <p style="text-align: center;">HTLV-1-induced innate dysfunction Helene Dutartre, France</p> <p style="text-align: center;">Molecular Virology of HTLV ZOOM - Benoit Barbeau, Canada</p> <p style="text-align: center;">Pathogenesis of HAM/TSP Christopher Itoh</p>
15:00 – 15:30	Coffee Break	

<p>15:30 – 17:30</p>	<p style="text-align: center;">Workshop 3 HTLV epidemiology, phylogenetics, and diagnostics <i>(Graham Taylor & Robert Harrod)</i></p> <p>Standardizing molecular diagnosis of HTLV infections Philippa Hetzel, Australia</p> <p>Contributions of Molecular Epidemiology and Sequence Analysis to HTLV-1 Research Philippe Afonso, France</p> <p>Diagnosis of HTLV infections in early life Carolina Rosadas, UK</p> <p>Pathogenesis of HAM/TSP and Its Implications for Drug Discovery Yoshi Yamano, Japan</p> <p>Molecular epidemiology of HTLV-1/2 in the Americas PRERECORD - Ricardo Ishak, Brazil</p> <p>Revision of the Japanese clinical practice guideline for HTLV-1– Associated Myelopathy Tomoo Sato, Japan</p> <p>IRVA Africa meeting, safety of blood transfusions in Africa and the need to inform public policy ZOOM - Jean-Claude Twizere</p>	<p style="text-align: center;">Workshop 4 Preclinical models, clinical guidelines, and trials <i>(Luis Malpica & R. Alejandro Sica)</i></p> <p>HTLV animal models (ATLL & HAM/TSP) Patrick Green, USA</p> <p>US National Cancer Research Network (NCCN) guidelines Steven Horwitz, USA</p> <p>Targeting Epigenetic and Other Pathways in ATLL Toshiki Watanabe, Japan</p> <p>Evidence-based treatment recommendations for ATLL Lucy Cook, London</p> <p>Advances in Stem Cell Transplant for ATLL Ali Bazarbachi, Lebanon</p> <p>Current & emerging therapeutic strategies for ATLL in USA Juan Carlos Ramos, USA</p> <p>Overview of Current clinical trials data Olivier Hermine, France</p>
<p>17:30 - 19:00</p>	<p style="text-align: center;">Welcome Reception Constantine N. Papadakis Integrated Sciences Building (PISB) 3245 Chestnut St, Philadelphia, PA 19104 Street View: https://maps.app.goo.gl/nY6y47EQ9kHSnt2a8</p>	

Day 2 - Thursday June 4th

George D. Behrakis Grand Hall/Creese Student Center, Drexel University, 3210 Chestnut St, Philadelphia, PA 19104.

08:30 – 09:30	Opening Ceremony
09:30- 10:00	Coffee Break
10:00 – 11:30	<p style="text-align: center;">Symposium 1 - Host pathogen interaction Chairs: Arnold Rabson and Lishomwa Ndhlovu</p> <p style="text-align: center;">10:00 – 10:15 – Investigating the role of PP2A-B56 in establishing HTLV-1 infection Goedele Maertens, Imperial College London, London, United Kingdom</p> <p style="text-align: center;">10:15 – 10:27 - CRM1 hijacking by HTLV-1 Rex reprograms the UPF1 helicase from antiviral to proviral functions Vincent Mocquet, INSERM, Lyon, France</p> <p style="text-align: center;">10:27 – 10:39 - Hijacking antiviral defense: a restriction factor that promotes clonal expansion in adult T-cell leukemia Alexis Fontaine, University of Liege, Liege, Belgium</p> <p style="text-align: center;">10:39 – 10:51 - Non-random organization of provirus-host 3D chromatin interactions across HTLV-1-infected clones Mateo Bazire, Laboratoire de Biologie et Modélisation de la Cellule (LBMC), Ecole Normale Supérieure de Lyon, France</p> <p style="text-align: center;">10:51 – 11:03 - Human breast milk prevents acid-induced cell death of HTLV-1 infected cells, enhances release of infectious virus and modulates the viral biofilm Franziska Wittdorf, Harald zur Hausen Institute of Virology, Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany</p> <p style="text-align: center;">11:03 – 11:15 - HTLV-1 Tax induces PINK1-Parkin-dependent mitophagy to mitigate activation of the cGAS-STING pathway Edward Harhaj, Penn State College of Medicine, Hershey, USA</p> <p style="text-align: center;">11:15 – 11:27 - Dendritic Cells Pulsed with HAM/TSP Exosomes Sensitize CD4 T Cells to Enhance HTLV-1 Infection, Induce Helper T-Cell Polarization, and Decrease Cytotoxic T-Cell Response Thomas Premeaux, Weill Cornell Medicine & Drexel Medicine, USA</p>

11:30 – 13:00	<p style="text-align: center;">Symposium 2 – Viral Proteins and Molecular Biology Chairs: Jianping Li and Louis Mansky</p> <p>11:30 – 11:45 - Structural Basis of Antibody Recognition of the HTLV Envelope ZOOM - Tongqing Zhou, National Institute of Allergy and Infectious Diseases, Bethesda, USA</p> <p>11:45 – 11:57 - Identification of key HTLV-1 integrase residues for catalysis, host factor binding, and intasome formation Aaron Mamane-Logsdon, Imperial College London, London, United Kingdom</p> <p>11:57 – 12:09 - Small-molecule modulators of BLV and HTLV proteases: from enzymatic screening to antiviral activity Camila Sagasti, Institut Pasteur de Montevideo, Montevideo, Uruguay Facultad de Medicina, UdelaR, Montevideo, Uruguay</p> <p>12:09 – 12:21 - HTLV-1C p16 protein contributes to virus production and dissemination Cynthia Pise-Masison, National Cancer Institute, Bethesda, USA</p> <p>12:21 – 12:33 - Whole genome HTLV-1 amplification using a simplified long-fragment polymerase chain reaction workflow optimized for next-generation sequencing Felice Deminco, Professor Edgard Santos University Hospital, Salvador, Brazil</p> <p>12:33 – 12:45 –PRMT5 regulates HTLV-1 p30 stability and cell cycle progression Bethany Pepple, The Ohio State University, Columbus, USA</p> <p>12:45 – 12:57 - Characterisation of proviral mutation diversity in HTLV-1-infected clones Anat Melamed, Imperial College London, London, United Kingdom</p>
13:00 – 14:00	Boxed Lunch
14:00 – 15:00	<p>Keynote Lecture Chimeric Antigen Receptor T-cell Immunotherapy for T-cell Malignancies Dr. Marco Ruella, MD CAR-T Therapy against Leukemia and Lymphoma Center for Cellular Immunotherapies, University of Pennsylvania (PennMedicine), Philadelphia, PA, USA</p>
15:00 – 18:00	Poster Session & Vendor exhibits (Papadakis integrated science building atrium)
18:00	IRVA EC Board Meeting/Free evening for rest

Day 3 – Friday June 5th

Pennsylvania Convention Centre, 1101 Arch Street.

Enter through the 12th Street & West Arch entrance, right across the famous Reading Terminal Market/Panera Bread

08:00 – 08:30	Morning Tea & Coffee
08:30 – 10:10	<p style="text-align: center;">Symposium 3 - Inflammation and HAM/TSP Chairs: Steve Jacobsen and Fatah Kashanchi</p> <p>08:30 – 08:42 - Senescence-driven inflammaging in HTLV-1 Infection: a multi-omics in vivo and in vitro signature Johan Van Weyenbergh, KU Leuven, Leuven, Belgium</p> <p>08:42 – 08:54 - Transcriptional reprogramming in immune cells of HTLV-1 asymptomatic carriers and HAM/TSP patients following antiretroviral therapy Sai Chaitanya Rajendra Gaekwar, Drexel Medicine, Philadelphia, USA</p> <p>08:54 – 09:06 - Cognitive Impairment associated with HTLV-1 infection: A case series with neuropsychological and advanced neuroimaging findings. Billy McBenedict, Fluminense Federal University, Niteroi, Brazil</p> <p>09:06 – 09:18 - Tyrosine kinase inhibitors induce apoptosis in HTLV-1-infected T cells from HAM/TSP patients via Bim Daisuke Kodama, Kagoshima University, Kagoshima City, Japan</p> <p>09:18 – 09:30 - Elucidating the relationship between neuroinflammation and brain white matter lesions in HTLV-1 infection Marzia Puccioni-Sohler, Univesidade Federal do Estado do Rio de Janeiro (UNIRIO), Rio de Janeiro, Brazil Univesidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil</p> <p style="text-align: center;">09:30 – 09:42 - HTLV-1 associated myositis: A case series Michael Wride, Imperial College Healthcare NHS Trust, London, United Kingdom</p> <p>09:42 – 09:54 - Single cell analysis of infected T cells from HAM/TSP patients Saiful Islam, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan</p> <p>09:54 – 10:09 - T-cell exhaustion and high Tim-3 expression defines HTLV-1c infection and pulmonary disease Ashley Hirons, Doherty Institute, Melbourne, Australia University of Melbourne, Melbourne, Australia</p>
10:10 – 10:40	Coffee Break

<p>10:40 – 12:20</p>	<p style="text-align: center;">Symposium 4 – Epidemiology/Diagnosis Chairs: Glen Barber and Bobby Brooke Herrera</p> <p>10:40 – 10:55 - Comparison of clinical features and outcomes of adult T-cell leukemia/lymphoma across world regions: An international retrospective cohort study Bryan Valcarcel, MD Anderson, Texas, USA</p> <p>10:55 – 11:07 - Population-based patterns of adult T-Cell leukemia/lymphoma in the United States Paulo Pinheiro, University of Miami School of Medicine, Miami, USA</p> <p>11:07 - 11:19 - A cross-sectional view of HTLV-1 infection across pediatric, adult, and pregnant populations in an endemic region of Colombia Juan P. Rojas-Hernández, Universidad del Valle, Cali, Colombia Universidad Libre seccional, Cali, Colombia Universidad San Martín, Cali, Colombia Pontificia Universidad Javeriana, Cali, Colombia</p> <p>11:19 – 11:31 - Prevalence of HTLV-1 infection among family members of people living with the virus: A systematic review and meta-analysis Fernanda Grassi, Oswaldo Cruz Foundation, Gonçalo Moniz Institute, Salvador, Brazil</p> <p>11:31 – 11:43 - Quantification of HTLV-proviral load in whole blood and dried blood spots: an alternative to peripheral blood mononuclear cells Momoko Usui, Imperial College London, London, United Kingdom</p> <p>11:43 – 11:55 - Evaluation and comparison of HTLV-1 proviral load using different methods Gabriel Franco, Federal University of Bahia, Salvador, Brazil</p> <p>11:55 – 12:07 - HTLV-I family cluster with varied outcomes and a potential exposure-related HTLV-I seroindeterminate status Jessica Cuenca-Iglesias, Instituto de Medicina Tropical “Alexander von Humboldt” (IMTAvH), Universidad Peruana Cayetano Heredia, Lima, Peru</p> <p>12:07 – 12:19 - Improving access to and quality of Molecular Testing for HTLV globally Mirna Biglione, CONICET–Universidad de Buenos Aires, Buenos Aires, Argentina</p>
<p>12:20 – 13:35</p>	<p>Lunch – open</p>

<p>13:35 – 15:15</p>	<p style="text-align: center;">Symposium 5 – Animal models Chairs: Patrick Green and Zafar Khan</p> <p style="text-align: center;">13:35 – 13:50 - DTG use is associated with sustained decrease in HTLV-1 proviral load, that persists after 6 months of therapy interruption ZOOM - Maria Arriaga, Federal University of Bahia, Salvador, Brazil</p> <p style="text-align: center;">13:50 – 14:02 - Contribution to lung inflammation of genetic determinants in the HTLV-1C envelope Genoveffa Franchini, National Cancer Institute, Bethesda, USA</p> <p style="text-align: center;">14:02 – 14:14 - Efficient induction of anti-HTLV-1 neutralizing antibodies by immunization with LNP-mRNA expressing a membrane-anchored Env SU trimer Hiroshi Ishii, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan</p> <p style="text-align: center;">14:14 – 14:26 - Combination antiretroviral therapy and MCL-1 inhibition mitigate HTLV-1 infection in vivo Marcel Doerflinger, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia</p> <p style="text-align: center;">14:26 – 14:38 - HTLV-1c Integration Rewires Host Nuclear Architecture and Enhancer Regulation in Infected T-Lymphocytes ZOOM - Natasha Jansz, The Doherty Institute - University of Melbourne, Melbourne, Australia</p> <p style="text-align: center;">14:38 – 14:50 - A small polypeptide encoded by antisense long non-coding RNAs mediates bovine leukemia virus replication Thomas Jouant, University of Liege, Gembloux, Belgium</p> <p style="text-align: center;">14:50 – 15:02 - HTLV-1 Hbz is a central determinant of viral persistence and oncogenic clonal expansion Cameron Phelps, The Ohio State University, Columbus, USA</p> <p style="text-align: center;">15:02 – 15:14 - Loss of viral enhancer and viral CTCF binding site impairs Hbz expression and HTLV-1 persistence Amanda Panfil, The Ohio State University, Columbus, USA</p>
<p>15:15- 15:45</p>	<p style="text-align: center;">Coffee Break</p>

<p>15:45 – 17:40</p>	<p style="text-align: center;">Symposium 6 – ATLL (General) Chairs: Pierluigi Porcu and Lucy Cook</p> <p>15:45 – 16:00 – Glucose dynamics predict Post-Transplant Relapse in ATL, revealing broad metabolic reprogramming confirmed by multi-cohort cross-omics analysis Kritika Subramanian, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium Albert Einstein College of Medicine, Bronx, USA</p> <p>16:00 – 16:12 - Towards the validation of the Viral Clonality Evenness (VCE) index: a novel prognostic biomarker for adult T-cell leukemia Anne-Sophie Reuter, GIGA, University of Liège, Liège, Belgium</p> <p>16:12 – 16:24 - Utility of flow cytometry for prognostic prediction in adult T-cell leukemia-IDrymphoma Shigeo Fuji, Osaka International Cancer Institute, Osaka, Japan</p> <p>16:24 – 16:36 - EP300 deficiency leads to chronic replication stress driven aggressive Adult T-cell leukemia/lymphoma Advaita Madireddy, Rutgers University, New Brunswick, USA</p> <p>16:36 – 16:48 - Genome-wide histone code remodelling in ATL and HAM/TSP Haozheng Liao, The University of Tokyo, Japan</p> <p>16:48 – 17:00 - Tax is expressed in uncultured CD7-/CADM1+ primary ATL cells and is critical for ATL survival Rita Hleihel, American University of Beirut, Faculty of Medicine, Beirut, Lebanon</p> <p>17:00 – 17:12 - Characterizing the Function Role of FOXO3 and its Clinical Implications in HTLV-1 Related Adult T-cell Leukemia-lymphoma Georgios Pongas, Department of Medicine, Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, USA</p> <p>17:12 – 17:24 - IRF4 drives inflammasome and suppresses pyroptosis in ATLL Daniel Rauch, Washington University, St Louis, USA</p> <p>17:24 – 17:36 - The role of EP300 in North American adult T-cell leukemia/lymphoma: downstream effector and therapeutic opportunity Shiang-Jie Yang, Albert Einstein College of Medicine, New York, USA</p>
<p>18:00</p>	<p style="text-align: center;">HTLV Walk to dinner location, Moshulu Restaurant near Penn’s lending</p>
<p>19:00</p>	<p style="text-align: center;">Gala Dinner - Moshulu Restaurant near Penns lending</p>

Day 4 - Saturday June 6th

Pennsylvania Convention Centre, 1101 Arch Street.

Enter through the 12th Street & West Arch entrance, right across the famous Reading Terminal Market/Panera Bread

08:00	Morning Tea & Coffee
08:30 – 10:25	<p style="text-align: center;">Symposium 7 – Therapeutic/ATLL Chairs: Juan C. Ramos and Vidyasagar Koduri</p> <p>08:30– 08:45 – First-in-Human CD70-Directed Allogeneic CAR T-Cell Therapy for HTLV-1 ATLL: Durable Responses and Molecular Evolution in the COBALT-LYM Trial R. Alejandro Sica, Montefiore Medical Center, NYC, USA</p> <p>08:45 – 08:57 - Immune evasion via the NKG2A–HLA-E axis and its potential as a novel immunotherapeutic target in adult T-cell leukemia-lymphoma (ATL) Takahisa Nakamura, Kumamoto University, Kumamoto, Japan</p> <p>08:57 – 09:09 - Role of a unique subset of cytolytic T cells in clinical response in the belinostat trial with zidovudine plus interferon for ATLL B. Hilda Ye, Albert Einstein College of Medicine, New York, USA</p> <p>09:09 – 09:21 - Kromastat, a Polymer Nanoparticle of Class 1 Selective HDAC Inhibitor, Demonstrates Marked Activity in Adult T Cell Leukemia/Lymphoma Rana Mhaidly, American University of Beirut, Beirut, Lebanon</p> <p>09:21 – 09:33 - Overcoming Adult T-Cell Leukemia/Lymphoma Survival Pathway with mTORC1 Blockade and BH3-Mimetics ZOOM - Arezoo Darbandi, Veneto Institute of Oncology IOV–IRCCS, Italy</p> <p>09:33 – 09:45 - Venetoclax-Based Therapeutic Strategies in Relapsed/Refractory North American Adult T-Cell Leukemia/Lymphoma Ankit Tanwar, Albert Einstein College of Medicine, New York, USA</p> <p>09:45 – 09:57 - Adult T-cell Leukaemia/Lymphoma Outcomes in the UK in 2025 Anna Weatherill, Imperial College London, London, United Kingdom Imperial College Healthcare NHS Trust, London, United Kingdom</p> <p>09:57 – 10:09 - Immunological biomarkers in people with HTLV-1 treated with Dolutegravir Carlos Brites, Federal University of Bahia, Salvador, Brazil</p> <p>10:09 – 10:21 – Long-term efficacy and safety of bexarotene in Japanese patients with adult T-cell leukemia-lymphoma: results from a phase II extension study (B-1901) Kentaro Yonekura, Imamura General Hospital, Kagoshima, Japan</p>

10:25 – 10:50	Coffee Break
10:50 – 12:20	<p style="text-align: center;">Symposium 8 – Policy/social impact/stigma Chairs: Goedele Maertens & Carol Rosadas</p> <p>10:50 – 11:05 - HTLV in Brazil: Recent advances in national policies for surveillance, antenatal care, and the elimination of vertical transmission Pâmela Gaspar, Department of HIV, AIDS, Tuberculosis, Viral Hepatitis, and Sexually Transmitted Infections, Secretariat for Health and Environmental Surveillance, Ministry of Health of Brazil, Brasília, Brazil</p> <p>11:05 – 11:17 - From invisibility to public policy: integrating HTLV into Brazil’s vertical transmission elimination certification process Mayra Aragon, General Coordination for Surveillance of Sexually Transmitted Infections, Department of HIV/AIDS, Tuberculosis, Viral Hepatitis and Sexually Transmitted Infections, Secretariat of Health Surveillance and Environment, Ministry of Health, Brasilia, Brazil</p> <p>11:17 – 11:29 - The HTLV Brazil Health Education Initiative: Multiple strategies for science communication and health education on HTLV and associated diseases Clarice N Lins de Moraes, Oswaldo Cruz Foundation- Fiocruz, Recife, PE, Brazil</p> <p>11:29 – 11:41 - A community-based partnership to assess knowledge about HTLV-1 and ATLL and perceptions about research among an at-risk population in Philadelphia Sean Reilly, Sidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University Hospital, Philadelphia, USA</p> <p>11:41 – 11:53 - Global disparities in HTLV-1 research and response: A unique focus on Caribbean and Polynesian/Japanese and Caribbean populations Ryan Hoffmann, Drexel University College of Medicine, Philadelphia, USA</p> <p>11:53 – 12:05 - Innovation and Health Cooperation to Strengthen Molecular Diagnosis of HTLV in the Brazilian Unified Health System (SUS) Renata Olivia Gadelha Romero, Rio Grande do Norte State Health Department, Natal, RN, Brazil</p> <p>12:05 – 12:17 - Strengthening community engagement to advance HTLV public policies in Brazil: from invisibility to national representation Mayra Gonçalves Aragón, Department of HIV, AIDS, Tuberculosis, Viral Hepatitis, and Sexually Transmitted Infections, Secretariat for Health and Environmental Surveillance, Ministry of Health of Brazil, Brasília, Brazil</p>
12:20 – 13:20	<p>Closing Ceremony / Vote of Thanks Next Conference IRVA AGM, Announcements & Awards</p>